Abstract
One of the neuropathological hallmarks of Alzheimer’s disease (AD) is the presence of brain senile plaques made up principally of aggregated amyloid beta (Aβ) peptides. Aβ is produced during the consecutive proteolysis of the transmembrane amyloid precursor protein (APP) by β- and γ-secretases. Genetic and pharmacological manipulations have demonstrated the major β -secretase in AD that makes the initial cleavage required for synthesis of Aβ is the beta-site APP-cleaving enzyme 1 (BACE1). It is therefore very tempting to consider inhibiting BACE1 as a potential AD therapeutic intervention. Here, we review the current knowledge and the molecular and physiological challenges associated with BACE1 inhibition. We also propose alternatives to the direct targeting of CNS BACE1 to prevent AD, as well as methods to measure the therapeutic efficacy of BACE1 inhibition.
Keywords: Amyloid, Alzheimer’s, APP, BACE1, bapineuzumab, beta-secretase, blood brain barrier, central nervous system, clinical trial, design, down syndrome, gamma-secretase, immunotherapy, inhibition, modulation, optimization, periphery, peptidomimetic, solanezumab, trafficking.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development